Reverse pharmacognosy: Another way to harness the generosity of nature

Current Pharmaceutical Design

Volumn 16, Issue 15, 2010, Pages 1682-1696

  Blondeau, S ^a,b,c   Do, Q T ^a   Scior, T ^d   Bernard, P ^a   Morin Allory, L ^b,c  

^a Greenpharma SA   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c CNRS   (France)

^d BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

Drug repositioning; Ethnopharmacology; Inverse screening; Natural compound database; Reverse pharmacognosy; Selnergy

Indexed keywords

ANTINEOPLASTIC AGENT; COUMARIN DERIVATIVE; MERANZIN; POLYPHENOL DERIVATIVE; ROSIGLITAZONE; UNCLASSIFIED DRUG; VINIFERIN; BIOLOGICAL PRODUCT; DRUG;

BIOASSAY; BRENDA; COMPUTER PROGRAM; DATA BASE; GREENPHARMA REVERSE PHARMACOGNOSY PLATFORM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; IC 50; INVDOCK; NUCLEAR MAGNETIC RESONANCE; PHARMACOLOGY; PRIORITY JOURNAL; REVERSE PHARMACOGNOSY; REVIEW; SELNERGY; TARFISDOCK; CHEMISTRY; DRUG DESIGN; DRUG INDUSTRY; FACTUAL DATABASE; METHODOLOGY; PHARMACOGNOSY;

BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DRUG DESIGN; DRUG INDUSTRY; PHARMACEUTICAL PREPARATIONS; PHARMACOGNOSY;

EID: 78049516864     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210791164036     Document Type: Review

References (108)

1. Harvey AL. Natural products in drug discovery. Drug Discov Today 2008; 13: 894-901.
2. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-20.
3. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci 2005; 78: 431-41.
4. Rates SMK. Plants as source of drugs. Toxicon 2001; 39: 603-13.
5. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 2008; 25: 475-516.
6. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003; 66: 1022-37.
7. Ganesan A. Natural products as a hunting ground for combinatorial chemistry. Curr Opin Biotechnol 2004; 15: 584-90.
8. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70:461-78.
9. Woodcock J, Woosley R. The FDA Critical Path Initiative and Its Influence on New Drug Development 2008; 59: 1-12.
10. Grabowski K, Baringhaus KH, Schneider G. Scaffold diversity of natural products: inspiration for combinatorial library design. Nat Prod Rep 2008; 25: 892-904.
11. Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull World Health Organ 1985; 63: 965-81.
12. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med 2006; 27: 1-93.
13. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000; 17: 215-34.
14. Feher M, Schmidt JM. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2009; 43: 218-27.
15. Tiew P, Ioset JR, Kokpol U, Chavasiri W, Hostettmann K. Antifungal, antioxidant and larvicidal activities of compounds isolated from the heartwood of Mansonia gagei. Phytother Res 2003; 17: 190-3.
16. Sartelet H, Serghat S, Lobstein A, Ingenbleek Y, Anton R, Petitfrere E. Flavonoids extracted from fonio millet (Digitaria exilis) reveal potent antithyroid properties. Nutrition 1996; 12: 100-6.
17. Larsson S, Backlund A, Bohlin L. Reappraising a decade old explanatory model for pharmacognosy. Phytochem Lett 2008; 1: 131-4.
18. Rollinger JM, Langer T, Stuppner H. Integrated in silico tools for exploiting the natural products' bioactivity. Planta Med 2006; 72: 671-8.
19. Rollinger JM, Langer T, Stuppner H. Strategies for efficient lead structure discovery from natural products. Curr Med Chem 2006; 13: 1491-507.
20. Rollinger JM, Haupt S, Stuppner H, Langer T. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example. J Chem Inf Comput Sci 2004; 44: 480-8.
21. Bernard P, Scior T, Didier B, Hibert M, Berthon JY. Ethno-pharmacology and bioinformatic combination for leads discovery: application to phospholipase A2 inhibitors. Phytochemistry 2001; 58: 865-74.
22. Do Q, Bernard P. Pharmacognosy and reverse pharmacognosy: a new concept for accelerating natural drug discovery. IDrugs 2004; 7: 1017-27.
23. Do QT, Renimel I, Andre P, Lugnier C, Muller CD, Bernard P. Reverse pharmacognosy: application of selnergy, a new tool for lead discovery. The example of epsilon-viniferin. Curr Drug Discov Technol 2005; 2: 161-7.
24. Do QT, Lamy C, Renimel I, Sauvan N, André P, Himbert F, et al. Reverse pharmacognosy: identifying biological properties for plants by means of their molecule constituents: application to meranzin. Planta Med 2007; 73: 1235-40.
25. nd ed. Paris: Lavoisier 1993.
26. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 2001; 109(Suppl 1): 69-75.
27. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci 2004; 86: 789-99.
28. Patwardhan B. Ethnopharmacology and drug discovery. J Ethnopharmacol 2005; 100: 50-2.
29. Vaidya A. Reverse pharmacological correlates of ayurvedic drug actions. Indian J Pharmacol 2006; 38: 311-5.
30. Patwardhan B, Mashelkar RA. Traditional medicine inspired approaches to drug discovery: can Ayurveda show the way forward? Drug Discov Today 2009; 14: 804-11.
31. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
32. Ortholand JY, Ganesan A. Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol 2004; 8: 271-80.
33. TM. Available at: http://www.iucnredlist.org/
34. Wermuth CG. Multitargeted drugs: the end of the "one-target-one-disease" philosophy? Drug Discov Today 2004; 9: 826-7.
35. Aschwanden C. Herbs for health, but how safe are they? Bull World Health Organ 2001; 79: 691-2.
36. The Open Babel Package, version 2.2.1. (http://openbabel.sourceforge.net) Oct 2009.
37. Steinbeck C, Hoppe C, Kuhn S, Floris M, Guha R, Willighagen EL. Recent developments of the chemistry development kit(CDK)-: An open-source java library for chemo- and bioinformatics. Curr Pharm Des 2006; 12: 2111-20.
38. Monge A, Arrault A, Marot C, Morin-Allory L. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol Divers 2006; 10: 389-403.
39. Tripos, Sybyl, version 8.0 (http://www.tripos.com/sybyl) Oct 2009.
40. ChemAxon (http://www.chemaxon.com) Oct 2009.
41. Sperandio O, Miteva MA, Delfaud F, Villoutreix BO. Receptor-based computational screening of compound databases: the main docking-scoring engines. Curr Protein Pept Sci 2006; 7: 369-94.
42. Tang Y, Zhu W, Chen K, Jiang H. New technologies in computer-aided drug design: toward target identification and new chemical entity discovery. Drug Discov Today: Technol 2006; 3: 307-13.
43. Pearlman RS, Balducci R, Rusinko A, Skell JM, Smith KM. CONCORD. St. Louis, MO: Tripos Associates 1994.
44. Sadowski J, Wagener M, Gasteiger J. CORINA: Automatic Generation of High-Quality 3D-Molecular Models for Application in QSAR. In: Sanz F, Giraldo J, Manaut F, Eds. QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications. Spain: Prous Science Publishers 1995; 646-51.
45. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 1996; 9: 1-5.
46. Ewing TJA, Makino S Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 2001; 15: 411-28.
47. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996; 261: 470-89.
48. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47: 1739-49.
49. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-48.
50. Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 2003; 46: 499-511.
51. Clark RD, Strizhev A, Leonard JM, Blake JF, Matthew JB. Consensus scoring for ligand/protein interactions. J Mol Graph Model 2002; 20: 281-95.
52. Vigers GPA, Rizzi JP. Multiple active site corrections for docking and virtual screening. J Med Chem 2004; 47: 80-9.
53. Kellenberger E, Foata N, Rognan D. Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems. J Chem Inf Model 2008; 48: 1014-25.
54. Chen X, Ung CY, Chen Y. Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients? Nat Prod Rep 2003; 20: 432-44.
55. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, et al. The protein data bank. Acta Crystallogr. Sect D: Biol Crystallogr 2002; 58: 899-907.
56. Li H, Gao Z, Kang L, Zhang H, Yang K, Yu K, et al. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res 2006; 34: 219-24.
57. EC. Enzyme nomenclature 1992: recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes, 1992.
58. Teague SJ. Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2003; 2: 527-41.
59. Carlson HA. Protein flexibility is an important component of structure-based drug discovery. Curr Pharm Des 2002; 8: 1571-8.
60. Claußen H, Buning C, Rarey M, Lengauer T. FlexE: efficient molecular dockingconsidering protein structure variations. J Mol Biol 2001; 308: 377-95.
61. Berman HM. The protein data bank: a historical perspective. Acta Crystallogr Sect A: Found Crystallogr 2008; 64: 88-95.
62. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
63. Goto S, Okuno Y, Hattori M, Nishioka T, Kanehisa M. LIGAND: database of chemicalcompounds and reactions in biological pathways. Nucleic Acids Res 2002; 30: 402-4.
64. Schomburg I, Chang A, Ebeling C, Gremse M, Heldt C, Huhn G, et al. BRENDA, the enzyme database: updates and major new developments. Nucleic Acids Res 2004; 32: 431-3.
65. Chang A, Scheer M, Grote A, Schomburg I, Schomburg D. Brenda, amenda and frenda the enzyme information system: new content and tools in 2009. Nucleic Acids Res 2009; 37: 588-92.
66. Chen X, Ji ZL, Chen YZ. TTD: therapeutic target database. Nucleic Acids Res 2002; 30: 412-5.
67. Gao Z, Li H, Zhang H, Liu W, Kang L, Luo X, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008; 9: 104.
68. Kellenberger E, Muller P, Schalon C, Bret G, Foata N, Rognan D. sc-PDB: an annotated database of druggable binding sites from the Protein Data Bank. J Chem Inf Model 2006; 46: 717-27.
69. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: 901-6.
70. Günther S, Kuhn M, Dunkel M, Campillos M, Senger C, Petsalaki E, et al. Super target and matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008; 36: 919-22.
71. Scior T, Bernard P, Medina-Franco JL, Maggiora GM. Large compound databases for structure-activity relationships studies in drug discovery. Mini Rev Med Chem 2007; 7: 851-60.
72. Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 2008; 36: 684-8.
73. STITCH, (http://stitch.embl.de) Oct 2009.
74. Thomas MB, Lin N, Beck HH. A database Model for integrating and facilitating collaborative ethnomedicinal research. Pharmaceutical Biol 2001; 39: 41-52.
75. Verpoorte R. Repository for ethnopharmacological survey data? J Ethnopharmacol 2008; 120: 127-8.
76. Skoczen S, Bussmann RW. ebDB-Filling the gap for an International Ethnobotany Database. Lyonia 2006; 11: 71-81.
77. Ji ZL, Zhou H, Wang JF, Han LY, Zheng CJ, Chen YZ. Traditional Chinese medicine information database. J Ethnopharmacol 2006; 103: 501.
78. Gry J, Black L, Eriksen FD, Pilegaard K, Plumb J, Rhodes M, et al. EuroFIR-BASIS - a combined composition and biological activity database for bioactive compounds in plant-based foods. Trends Food Sci Technol 2007; 18: 434-44.
79. Babu PA, Puppala SS, Aswini SL, Vani MR, Kumar CN, Prasanna T. A database of natural products and chemical entities from marine habitat. Bioinformation 2008; 3: 142-3.
80. Lei J, Zhou J. A marine natural product database. J Chem Inf Comput Sci 2002; 42: 742-8.
81. Taylor L. The Tropical Plant Database (http://www.rain-tree.com/plants.htm) Oct 2009.
82. Holden JM, Eldridge AL, Beecher GR, Marilyn Buzzard I, Bhagwat S, Davis CS, et al. Carotenoid content of US foods: an update of the database. J Food Compost Anal 1999; 12: 169-96
83. J. Dr. Duke's phytochemical and ethnobotanical databases. ARS, USDA (http://www.ars-grin.gov/duke) Oct 2009.
84. Buckingham J. Dictionary of natural products. London: Chapman & Hall; 1994.
85. Loub WD, Farnsworth NR, Soejarto DD, Quinn ML. NAPRALERT: computer handling of natural product research data. J Chem Inf Comput Sci 1985; 25: 99-103.
86. Farnsworth N. The Napralert database as an information source for application to traditional medicine. OMS Geneva, Switzerland 1993.
87. Plant for a future database (http://www.pfaf.org) Oct 2009.
88. Dunkel M, Fullbeck M, Neumann S, Preissner R. SuperNatural: a searchable database of available natural compounds. Nucleic Acids Res 2006; 34: 678-683.
89. Jmol, version 11.2.14 (http://www.jmol.org) Oct 2009.
90. Mishima S, Matsumoto K, Futamara Y, Araki Y, Ito T, Tanaka T, et al. Antitumor effect of stilbenoids from Vateria indica against allografted sarcoma S-180 in animal model. J Exp Ther Oncol 2003; 3: 283-8.
91. Privat C, Telo JP, Bernardes-Genisson V, Vieira A, Souchard JP, Nepveu F. Antioxidant properties of trans-[epsilon]-viniferin as compared to stilbene derivatives in aqueous and nonaqueous media. J Agric Food Chem 2002; 50: 1213-7.
92. Tanaka T, Ito T, Ido Y, Son TK, Nakaya K, Iinuma M, et al. Stilbenoids in the stem bark of Hopea parviflora. Phytochemistry 2000; 53: 1015-19.
93. Aminah NS, Achmad SA, Aimi N, Ghisalberti EL, Hakim EH, Kitajima M, et al. Diptoindonesin A, a new C-glucoside of epsilon-viniferin from Shorea seminis (Dipterocarpaceae). Fitoterapia 2002; 73: 501-7.
94. Tanaka T, Ito T, Nakaya K, Iinuma M, Riswan S. Oligostilbenoids in stem bark of Vatica rassak. Phytochemistry 2000; 54: 63-9.
95. Tanaka T, Ito T, Iinuma M, Ohyama M, Ichise M, Tateishi Y. Stilbene oligomers in roots of Sophora davidii. Phytochemistry 2000; 53: 1009-14.
96. Huang KS, Wang YH, Li RL, Lin M. Five new stilbene dimers from the lianas of Gnetum hainanense. J Nat Prod 2000; 63: 86-9.
97. Ali Z, Tanaka T, Iliya I, Iinuma M, Furusawa M, Ito T, et al. Phenolic constituents of Gnetum klossii. J Nat Prod 2003; 66: 558-60.
98. Iliya I, Ali Z, Tanaka T, Iinuma M, Furusawa M, Nakaya K, et al. Stilbenoids from the stem of Gnetum latifolium (Gnetaceae). Phytochemistry 2002; 61: 959-61.
99. Oshima Y, Namao K, Kamijou A, Matsuoka S, Nakano M, Terao K, et al. Powerful hepatoprotective and hepatotoxic plant oligostilbenes, isolated from the Oriental medicinal plant Vitis coignetiae (Vitaceae). Cell Mol Life Sci 1995; 51: 63-6.
100. Yang JZ, Zhou LX, Ding Y. Studies on chemical constituents of oligostilbenes from Vitis davidii Foex. Zhongguo Zhong yao za zhi 2001; 26: 553-5.
101. Li W, Li B. Flexuosol A, a new tetrastilbene from Vitis flexuosa. J Nat Prod 1998; 61:646-7.
102. Huang YL, Tsai WJ, Shen CC, Chen CC. Resveratrol derivatives from the roots of Vitis thunbergii. J Nat Prod 2005; 68: 217-20.
103. Langcake P. Disease resistance of Vitis spp. and the production of the stress metabolites resveratrol, epsilon-viniferin, alpha-viniferin and pterostilbene. Physiol Plant Pathol 1981; 18: 213-26.
104. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem Pharmacol 2001; 62: 1433-8.
105. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR. PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 1997; 46: 1230-4.
106. Teng WY, Chen CC, Chung RS. HPLC comparison of supercritical fluid extraction and solvent extraction of coumarins from the peel of Citrus maxima fruit. Phytochem Anal 2005; 16: 459-62.
107. Wickramaratne DBM, Kumar V, Balasubramaniam S. Murra-gleinin, a Coumarin fromMurraya gleinei Leaves. Phytochemistry 1984; 23: 2964-6.
108. Street RA, Stirk WA, Van Staden J. South African traditional medicinal plant trade-Challenges in regulating quality, safety and efficacy. J Ethnopharmacol 2008; 119: 705-10.